神州細胞(688520.SH):2024年度淨利潤1.12億元
格隆匯2月24日丨神州細胞(688520.SH)公佈2024年度業績快報,報告期內,公司實現營業總收入25.13億元,同比增長33.13%;實現歸屬於母公司所有者的淨利潤1.12億元,歸屬於母公司所有者的扣除非經常性損益的淨利潤4.74億元,較上年同期相比均實現扭虧爲盈。
報告期內,公司核心產品安佳因®銷售穩定,其他上市產品的銷售收入增加,公司整體營業收入較上年同期上升。爲加大已上市產品的市場推廣力度,以及爲即將商業化的產品擴充銷售隊伍,報告期內公司的銷售費用有所增加。報告期內,公司陸續有多個產品獲準開展臨牀研究,雖然研發投入仍保持較高水平,但現有管線產品多數尚在早期臨牀研究階段,資金投入相對較少,故整體研發投入較上年同期有所下降。與此同時,公司積極通過控制運營成本、提高研發效率等方式實現降本增效。這些因素均對公司經營產生影響,並使得公司預計2024年度實現扭虧爲盈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.